linvoseltamab
Selected indexed studies
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. (J Clin Oncol, 2024) [PMID:38879802]
- Linvoseltamab: First Approval. (Drugs, 2025) [PMID:40880034]
- An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma. (Expert Opin Biol Ther, 2025) [PMID:39923122]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. (2024) pubmed
- Linvoseltamab: First Approval. (2025) pubmed
- An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma. (2025) pubmed
- Linvoseltamab (Lynozyfic) for multiple myeloma. (2025) pubmed
- Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. (2025) pubmed
- Antibodies to watch in 2024. (2024) pubmed
- Erratum: Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. (2024) pubmed
- Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. (2026) pubmed
- Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies. (2025) pubmed
- Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. (2025) pubmed